New York, NY – April 17, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that Axiom Capital Management Inc. has completed a private placement of MabVax Therapeutics Holdings, Inc. (OTC: MBVX) Units. MabVax is a clinical-stage biopharmaceutical company focused on developing vaccine and monoclonal anti-body based therapeutics. The private placement consisted of 15,486,001 Units offered at $0.75 per Unit for aggregate proceeds of $11,714,501. Additionally, each Unit consisted of one share of common stock and a 30-month warrant to purchase one-half of one share of common stock where the warrants are exercisable at $1.50 per each whole share of common stock.
The private placement was led by OPKO Health, Inc. (NYSE: OPK) and the Frost Gamma Investments Trust. Sichenzia Ross Friedman Ference LLP Partners Harvey Kesner, Tara Guarneri-Ferrara, Associate Tim O’Brien and Foreign Attorney Ekaterina Williams represented Axiom Capital Management.
To learn more about SRFK, visit www.srf.law, SRFK’s LinkedIn and our Twitter page: @SRFKLLP
Media Contact:
pr@srf.law
(212)-930-9700
[starbox id=1]
